Katia Bruna B.
- Country
- Italy
- Department
- SC Oncologia Falk
Research Overview
- Pumitamig and Combination Therapy Versus Bevacizumab and Combination Therapy in Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Switch Maintenance with Paclitaxel, Ramucirumab and Tislelizumab vs Continued Chemotherapy plus Tislelizumab in HER2‑negative, PD‑L1‑positive Gastroesophageal Adenocarcinoma
- Evaluation of Trastuzumab Deruxtecan and Fluoropyrimidine Versus Standard Chemotherapy in HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease
Data & Insights
Has run more than one trial at 123 of 253 partner sites.
Specializations
Pancreatic Cancer Research
Specializes in the treatment of pancreatic ductal adenocarcinoma, with particular focus on advanced disease management. Investigates innovative therapeutic approaches combining chemotherapy regimens including modified FOLFIRINOX and targeted combinations.
- Pre-operative treatment strategies
- Advanced pancreatic cancer management
- Maintenance therapy approaches
Gastric Cancer Innovations
Focuses on treating gastric and gastroesophageal junction cancers, particularly in advanced and metastatic settings. Explores novel therapeutic approaches involving HER2-targeted treatments and innovative protein-targeted therapies.
- HER2-positive gastric cancer treatment
- Targeted molecular therapies
- Advanced disease management
Biliary Tract Oncology
Specializes in the treatment of biliary tract cancers, including both intrahepatic and extrahepatic cholangiocarcinoma. Investigates post-surgical therapeutic approaches combining immunotherapy with conventional chemotherapy.
- Post-surgical treatment strategies
- Adjuvant therapy development
- Gallbladder cancer management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.